Glossary

AJAX progress indicator
Search:
(clear)
  • MisconductScientific misconduct is unethical behaviour or the failure to follow established guidelines (such as Good Clinical Practice) in scientific research.Misconduct includes making things up, changing or lying about research, or copying the work of others (plagiarism). It also includes the failure(...)
  • Molecular biomarkerA biological marker, or biomarker, is something that can be measured, which points to the presence of a disease, a physiological change, response to a treatment, or a psychological condition.A molecular biomarker is a molecule that can be used in this way; for example, glucose levels are used(...)
  • Multi-Arm Multi-StageMulti-Arm Multi-Stage (MAMS) trials have a specific design that allows for several different treatments to be evaluated simultaneously against the standard treatment in a single trial. [mla_gallery meta_key="eupasset_name" meta_value="mams" columns="1" mla_caption="{+caption+}" link="file"(...)
  • MAMSMulti-Arm Multi-Stage (MAMS) trials have a specific design that allows for several different treatments to be evaluated simultaneously against the standard treatment in a single trial. [mla_gallery meta_key="eupasset_name" meta_value="mams" columns="1" mla_caption="{+caption+}" link="file"(...)
  • Multiple Ascending DoseMultiple Ascending Dose
  • MADMultiple Ascending Dose
  • MultiplicityMultiplicity occurs in clinical trials when a single clinical trial has several objectives, such as: assessing several different doses of a treatment, using several different endpoints to measure different aspects of a disease, or looking at several different subgroups of patients.Multiplicity(...)
  • Mutual recognition procedureThe mutual recognition procedure is the system for medicines authorisation by individual member states (Concerned Member States) recognising the authorisation of another member state (the Reference Member State) which has evaluated and authorised a new medicine.
  • MRPThe mutual recognition procedure is the system for medicines authorisation by individual member states (Concerned Member States) recognising the authorisation of another member state (the Reference Member State) which has evaluated and authorised a new medicine.
  • National Cancer InstitutePart of the US National Institutes of Health. http://www.cancer.gov/"

Find Out More